Free Trial

Indaptus Therapeutics (INDP) Competitors

Indaptus Therapeutics logo
$11.19 +0.04 (+0.36%)
Closing price 03:55 PM Eastern
Extended Trading
$11.69 +0.50 (+4.47%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INDP vs. MRNS, MAAQ, GRCE, ALLK, RANI, INKT, DYAI, SCYX, SXTC, and ENLV

Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Grace Therapeutics (GRCE), Allakos (ALLK), Rani Therapeutics (RANI), MiNK Therapeutics (INKT), Dyadic International (DYAI), SCYNEXIS (SCYX), China SXT Pharmaceuticals (SXTC), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.

Indaptus Therapeutics vs. Its Competitors

Marinus Pharmaceuticals (NASDAQ:MRNS) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Marinus Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.

In the previous week, Indaptus Therapeutics had 5 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 5 mentions for Indaptus Therapeutics and 0 mentions for Marinus Pharmaceuticals. Indaptus Therapeutics' average media sentiment score of 0.37 beat Marinus Pharmaceuticals' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Marinus Pharmaceuticals Neutral
Indaptus Therapeutics Neutral

Marinus Pharmaceuticals presently has a consensus price target of $3.92, indicating a potential upside of 613.29%. Indaptus Therapeutics has a consensus price target of $238.00, indicating a potential upside of 2,026.90%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than Marinus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marinus Pharmaceuticals
0 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40
Indaptus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Indaptus Therapeutics has lower revenue, but higher earnings than Marinus Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22
Indaptus TherapeuticsN/AN/A-$15.02M-$1.49-7.51

Indaptus Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Indaptus Therapeutics' return on equity of -333.02% beat Marinus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals-446.48% -7,831.35% -120.74%
Indaptus Therapeutics N/A -333.02%-216.36%

Summary

Indaptus Therapeutics beats Marinus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDP vs. The Competition

MetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.38M$2.42B$5.54B$8.87B
Dividend YieldN/A1.77%5.39%4.10%
P/E Ratio-0.278.7226.1419.88
Price / SalesN/A663.86414.67113.66
Price / CashN/A151.5836.1356.90
Price / Book1.034.548.055.38
Net Income-$15.02M$31.16M$3.15B$248.50M
7 Day Performance8.60%0.15%1.85%2.97%
1 Month Performance17.40%8.81%4.81%6.02%
1 Year Performance-81.50%2.55%34.86%20.39%

Indaptus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDP
Indaptus Therapeutics
3.0528 of 5 stars
$11.19
+0.4%
$238.00
+2,026.9%
-82.0%$6.38MN/A-0.276News Coverage
Gap Down
MRNS
Marinus Pharmaceuticals
2.2716 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-57.1%$30.32M$30.99M-0.22110
MAAQ
Mana Capital Acquisition
N/A$3.71
-4.6%
N/A+554.5%$30.14MN/A0.001Gap Up
GRCE
Grace Therapeutics
2.1862 of 5 stars
$2.96
+1.0%
$12.00
+305.4%
N/A$30.01MN/A-2.55N/APositive News
ALLK
Allakos
2.8267 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
RANI
Rani Therapeutics
2.2325 of 5 stars
$0.51
+3.5%
$7.33
+1,346.4%
-86.6%$29.14M$1.03M-0.51110Positive News
INKT
MiNK Therapeutics
3.4156 of 5 stars
$7.34
+1.0%
$37.50
+411.2%
-18.9%$29.03MN/A-2.8930Positive News
Gap Down
DYAI
Dyadic International
2.6237 of 5 stars
$0.96
+1.9%
$6.00
+527.6%
-36.6%$28.77M$3.49M-4.787News Coverage
SCYX
SCYNEXIS
0.7542 of 5 stars
$0.73
+0.4%
N/A-64.1%$28.72M$3.75M-1.3160Positive News
Gap Up
SXTC
China SXT Pharmaceuticals
0.3514 of 5 stars
$1.81
-1.9%
N/A-77.1%$28.19M$1.93M0.0090Gap Down
ENLV
Enlivex Therapeutics
3.3196 of 5 stars
$1.18
+1.3%
$10.00
+751.1%
-18.8%$27.79MN/A-1.7870Gap Up

Related Companies and Tools


This page (NASDAQ:INDP) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners